Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Tourmaline Bio Inc (NASDAQ: TRML) was $16.53 for the day, up 6.37% from the previous closing price of $15.54. In other words, the price has increased by $6.37 from its previous closing price. On the day, 0.66 million shares were traded. TRML stock price reached its highest trading level at $16.56 during the session, while it also had its lowest trading level at $15.22.
Ratios:
Our analysis of TRML’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 40.33 and its Current Ratio is at 40.33. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on December 06, 2024, initiated with a Outperform rating and assigned the stock a target price of $50.
On November 11, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $48 to $49.
On December 15, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $41.Jefferies initiated its Buy rating on December 15, 2023, with a $41 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 21 ’24 when Kulkarni Sandeep Chidambar bought 1,779 shares for $14.85 per share. The transaction valued at 26,418 led to the insider holds 7,000 shares of the business.
Kulkarni Sandeep Chidambar bought 5,221 shares of TRML for $71,998 on Aug 16 ’24. The CEO now owns 5,221 shares after completing the transaction at $13.79 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRML now has a Market Capitalization of 423872192 and an Enterprise Value of 142238336.
Stock Price History:
The Beta on a monthly basis for TRML is 2.34, which has changed by -0.5587734 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, TRML has reached a high of $48.31, while it has fallen to a 52-week low of $12.12. The 50-Day Moving Average of the stock is -20.86%, while the 200-Day Moving Average is calculated to be -13.51%.
Shares Statistics:
TRML traded an average of 212.57K shares per day over the past three months and 246300 shares per day over the past ten days. A total of 25.64M shares are outstanding, with a floating share count of 15.60M. Insiders hold about 39.16% of the company’s shares, while institutions hold 63.58% stake in the company. Shares short for TRML as of 1736899200 were 2329489 with a Short Ratio of 10.96, compared to 1734048000 on 1644638. Therefore, it implies a Short% of Shares Outstanding of 2329489 and a Short% of Float of 10.190000000000001.
Earnings Estimates
A comprehensive evaluation of Tourmaline Bio Inc (TRML) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.63 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$2.52 and -$3.77 for the fiscal current year, implying an average EPS of -$2.97. EPS for the following year is -$3.54, with 6.0 analysts recommending between -$1.46 and -$4.66.